Alcami, a U.S.-based contract development and manufacturing organization (CDMO), said it is providing commercial manufacturing services for Trevena’s newly approved OLINVYK. OLINVYK (oliceridine) injection is an opioid approved in adults for the management of acute pain severe enough to require an intravenous opioid analgesic. Alcami has provided development and clinical support for this program for several years leading up to Trevena’s approval from the U.S. FDA.
 
“For Alcami, this is another example of our ability to partner with customers to provide comprehensive support services from development through commercial approval,” said Walt Kaczmarek, chief executive officer, Alcami. “We congratulate Trevena on their novel product offering and important advancement in pain therapy and are proud to offer our expertise and support.”